Antibe Therapeutics Profit Margin 2014-2021 | ATBPF

Current and historical gross margin, operating margin and net profit margin for Antibe Therapeutics (ATBPF) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Antibe Therapeutics net profit margin as of September 30, 2021 is -244.59%.
Antibe Therapeutics Annual Profit Margins
Antibe Therapeutics Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.031B $0.008B
Antibe Therapeutics Inc. is a biotech company with a drug platform of therapeutics in pain and inflammation. Its lead drug candidate consists of ATB-346, non-addictive drug for chronic pain and inflammation; ATB-352, for a non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. Antibe Therapeutics Inc. is based in Toronto, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.033B 9.10
Bio-Rad Laboratories (BIO.B) United States $17.971B 36.47
QIAGEN (QGEN) Netherlands $11.044B 18.70
Biohaven Pharmaceutical Holding (BHVN) United States $7.729B 0.00
Emergent Biosolutions (EBS) United States $2.541B 9.14
Arcus Biosciences (RCUS) United States $2.414B 0.00
Myovant Sciences (MYOV) United Kingdom $1.374B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.167B 0.00
Zymeworks (ZYME) Canada $0.623B 0.00
Ambrx Biopharma (AMAM) United States $0.231B 0.00
SQZ Biotechnologies (SQZ) United States $0.214B 0.00
Enzo Biochem (ENZ) United States $0.161B 20.75